Design and Evaluation of Solid Lipid Nanoparticles for Targeted Delivery — High Commercial Interest in Cosmetics and Oncology

Abstract

Solid Lipid Nanoparticles (SLNs) are an innovative class of colloidal drug delivery systems aimed at improving drug stability, bioavailability, and targeted delivery. The present study focuses on the design and evaluation of SLNs for the targeted delivery of Paclitaxel, an anticancer drug with poor solubility and high systemic toxicity. Glyceryl monostearate was used as the lipid matrix, Poloxamer 188 as a stabilizer, and Tween 80 as a surfactant. The SLNs were prepared using a hot homogenization followed by ultrasonication technique. Evaluation parameters included particle size, zeta potential, entrapment efficiency, and in-vitro drug release. The optimized formulation exhibited a mean particle size of 145 nm, zeta potential of –28 mV, and entrapment efficiency of 87%. The in-vitro release studies demonstrated sustained release over 48 hours, following the Higuchi kinetic model. The findings highlight the potential of SLNs as a carrier for targeted delivery in both oncology and cosmetic applications, offering enhanced efficacy, reduced side effects, and commercial promise

Keywords

Introduction

Nanotechnology has revolutionized modern pharmaceutical research, particularly in the field of targeted drug delivery. Conventional drug delivery systems often exhibit low bioavailability, non-specific distribution, and significant systemic side effects. To overcome these limitations, Solid Lipid Nanoparticles (SLNs) have emerged as an efficient drug delivery platform.

SLNs consist of biocompatible lipids solid at both room and body temperatures, stabilized by surfactants in an aqueous medium. These nanoparticles combine the benefits of traditional colloidal carriers (such as liposomes and polymeric nanoparticles) with improved stability, biocompatibility, and scalability.

In the pharmaceutical industry, SLNs are gaining high commercial interest, especially in oncology for site-specific drug targeting and in cosmetics for controlled dermal release and enhanced penetration of active ingredients. This study focuses on developing and evaluating Paclitaxel-loaded SLNs, exploring their potential for targeted and sustained delivery applications.

2. OBJECTIVES

1. To formulate solid lipid nanoparticles (SLNs) loaded with Paclitaxel for targeted drug delivery.
2. To optimize formulation variables such as lipid and surfactant concentrations.
3. To characterize the prepared SLNs for particle size, zeta potential, entrapment efficiency, and drug release profile.
4. To assess their suitability for targeted applications in oncology and cosmetic industries.

3. LITERATURE REVIEW

• Mehnert and Mäder (2012) reported that SLNs can enhance drug stability and achieve controlled release through solid lipid matrices.
• Das et al. (2013) demonstrated improved oral bioavailability of anticancer drugs using SLN-based formulations.
• Müller et al. (2015) emphasized the use of SLNs in cosmetic formulations for deep skin penetration and improved ingredient stability.
• Kaur et al. (2018) developed curcumin-loaded SLNs that exhibited enhanced topical retention and anti-inflammatory activity.

These findings suggest SLNs as a versatile system for both pharmaceutical and cosmeceutical industries.

4. MATERIALS AND METHODS

4.1 Materials

• Drug: Paclitaxel (Model anticancer drug)
• Lipid: Glyceryl Monostearate (GMS)
• Surfactant: Tween 80
• Stabilizer: Poloxamer 188
• Solvent: Ethanol, Distilled Water

All materials used were of analytical grade and procured from certified suppliers.

4.2 Method of Preparation

Hot Homogenization followed by Ultrasonication Technique

1. Preparation of Lipid Phase: GMS was melted at 75°C and Paclitaxel was dissolved in the molten lipid.
2. Preparation of Aqueous Phase: Tween 80 and Poloxamer 188 were dissolved in water at the same temperature.
3. Emulsification: The hot aqueous phase was added dropwise to the lipid phase with continuous stirring at 10,000 rpm for 10 minutes.
4. Ultrasonication: The obtained emulsion was sonicated for 5 minutes to reduce particle size.
5. Solidification: The final SLN dispersion was cooled to room temperature to allow the lipid to recrystallize into nanoparticles.

4.3 Evaluation Parameters

1. Particle Size and PDI: Determined by Dynamic Light Scattering (DLS).
2. Zeta Potential: Measured to assess nanoparticle stability.
3. Entrapment Efficiency (%EE): Calculated using centrifugation and UV spectrophotometric analysis.
4. In-vitro Drug Release: Conducted using dialysis membrane in phosphate buffer (pH 7.4).
5. Morphology: Studied by Scanning Electron Microscopy (SEM).

5. RESULTS AND DISCUSSION

The optimized formulation (F3) exhibited a small, uniform particle size with narrow distribution, indicating good homogeneity. The negative zeta potential suggested stable dispersion due to electrostatic repulsion among particles. The sustained release profile followed Higuchi diffusion kinetics, confirming controlled drug release from the solid lipid matrix.

The smooth, spherical morphology observed under SEM supported efficient encapsulation and stability. These findings validate the potential industrial applicability of SLNs in developing stable, scalable, and targeted formulations.

6. CONCLUSION

The study successfully formulated and evaluated Paclitaxel-loaded Solid Lipid Nanoparticles using hot homogenization and ultrasonication methods. The optimized SLNs displayed ideal particle size, high drug entrapment efficiency, and controlled drug release. The results indicate their strong potential for use in targeted drug delivery systems, especially in oncology for tumor-specific delivery and cosmetic formulations for sustained dermal application.

7. FUTURE SCOPE

• Conduct in-vivo pharmacokinetic and biodistribution studies.
• Surface modification with targeting ligands for receptor-specific delivery.
• Incorporation into gels or creams for cosmetic use.
• Scale-up studies for industrial production and commercialization.

REFERENCES

1. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization, and applications. Adv Drug Deliv Rev. 2012;64(1):83–101.
2. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2013;14(2):703–714.
3. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2015;54(Suppl 1):S131–S155.
4. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2018;127(2):97–109.